Most women, regardless of age, are now offered screening for neonatal abnormalities in the early stages of pregnancy. To do this, a blood test taken between 10 and 14 weeks of pregnancy offers diagnostic testing using either chorionic villus sampling (if less than 13 weeks of gestation) or amniocentesis (if beyond 15 weeks of gestation). These procedures carry a risk of miscarriage and, therefore, it is important to be as accurate as possible with the initial testing, so as not to put expectant mothers through these intrusive tests unnecessarily. Acusera Maternal Screening Quality Control can help to ensure that the laboratory's results are accurate and reliable.
The Acusera Maternal Screening Quality Control has assayed target values and ranges provided for six parameters used in both first and second trimester screening for neonatal abnormalities. This multi-analyte control has been designed for use in the routine monitoring of accuracy and precision in prenatal testing and is compatible for use on a wide range of clinical chemistry and immunoassay systems.
Benefits of Acusera Maternal Screening Quality Control:
- Lyophilized for enhanced stability
- 100 percent human serum ensuring the control acts in the same manner as a patient sample
- Clinically relevant levels to assess the full clinical range
- AFP, Free -hCG, Inhibin A, PAPP-A, Total hCG and Unconjugated Estriol are all included in this control, consolidating up to three competitor controls to one Acusera control
- Stable to expiry date ensuring lot to lot consistency
- Reconstituted stability of 7 days at 2°C–8°C reducing waste in the laboratory